Source-linked reviews of peptide literature, analytical methods, study design, and research standards.
A practical, evidence-focused reading guide to scientific studies, certificates of analysis, analytical testing, and the limits of published findings.
A newly published randomized Phase 3 trial found that the C-type natriuretic peptide analogue vosoritide increased linear growth in children with hypochondroplasia. Here is what the evidence shows, what remains uncertain, and why this study matters for peptide drug development.
FDA approval of rusfertide (Mimrylo) brings a peptide designed to mimic the iron-regulatory hormone hepcidin into clinical use for erythrocytosis in adults with polycythemia vera. Here is what the randomized evidence shows, what remains uncertain, and why this mechanism matters for peptide science.
Evidence status: High-quality randomized Phase 3 evidence is now peer reviewed, but 177Lu-edotreotide (ITM-11) remains investigational in the United States. In August 2026, FDA issued a Complete Response Letter (CRL) for its New Drug Application. According to the sponsor, the CRL cited chemistry, manufacturing and controls (CMC) and third-party facility inspection issues, with no additional […]
Evidence status: FDA accelerated approval in February 2026, supported by a randomized, placebo-controlled pivotal trial and earlier randomized Phase 2 evidence. The approval is specifically for increasing linear growth in pediatric patients age 2 years and older with achondroplasia and open epiphyses. Continued approval depends on confirmation of clinical benefit, including an ongoing study of […]
Evidence status: Petrelintide (ZP8396) is an investigational, long-acting amylin analog being developed for chronic weight management. The most important current efficacy update comes from the randomized Phase 2 ZUPREME-1 trial, but the detailed results available as of September 2026 are sponsor-reported topline data, not yet a peer-reviewed full Phase 2 publication. Petrelintide is not FDA-approved. […]
Evidence status/context: Elamipretide (Forzinity) is a mitochondria-targeted tetrapeptide that received FDA accelerated approval on September 19, 2025 for improving muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. This is an important milestone for peptide science because it moves beyond receptor agonism and targets mitochondrial membrane biology. The approval […]
CagriSema combines the investigational amylin analogue cagrilintide with semaglutide. Peer-reviewed phase 3 trials show substantial weight reduction, while a 2026 sponsor-reported head-to-head trial did not meet non-inferiority versus tirzepatide. Here is what the evidence supports, what remains uncertain, and what researchers should watch next.
A source-linked review of maridebart cafraglutide (MariTide), including peer-reviewed Phase 2 results, sponsor-reported second-year maintenance findings, and the expanding Phase 3 MARITIME program.
A source-linked review of pemvidutide’s peer-reviewed Phase 2b MASH evidence, 48-week metabolic signals, FDA Breakthrough Therapy designation, and the questions Phase 3 must answer.